Nuclease-resistant synthetic ribozymes: Developing a new class of therapeutics

Journal of Clinical Investigation

Volumn 106, Issue 10, 2000, Pages 1197-1202

  Usman, Nassim ^a   Blatt, Lawrence M ^a  

^a Sirna Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOZYME; HEPTAZYME; MESSENGER RNA; NUCLEASE; RIBOZYME; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; CATALYSIS; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA SEQUENCE; TREATMENT OUTCOME; VIRUS INFECTION;

EID: 0033692912     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI11631     Document Type: Review

References (25)

1. In vitro splicing of the ribosomal RNA precursor of Tetrahymena: Involvement of a guanosine nucleotide in the excision of the intervening sequence
2. The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme
3. Ribozyme engineering
4. Design, synthesis and function of therapeutic hammerhead ribozymes
5. Chemical modification of hammerhead ribozymes: Catalytic activity and nuclease resistance
6. Catalytic RNA (ribozymes) as drugs
7. Antisense oligonucleotide inhibitors for the treatment of cancer. II. Toxicological properties of phosphororhioate oligodeoxynucleotides
8. Synthesis, deprotection, analysis and purification of RNA and ribozymes
9. Tumor angiogenesis: Therapeutic implications
10. Vascular endothelial growth factor, a potent and selective angiogenic agent
11. The regulation of blood vessel growth by vascular endothelial growth factor
12. Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors
13. Bioactivity of antiangiogenic ribozymes targeting Flt-1 and KDR mRNA
14. Pharmacokinetics and tolerability of an antiangiogenic ribozyme (ANGIOZYME) in healthy volunteers
15. A phase I/II study of repetitive dose Angiozyme(TM), a ribozyme targeting the Flt-1 receptor for VEGF
16. Viral hepatitis
17. Hepatitis C: The clinical spectrum of disease
18. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome
19. Sequence analysis of the 5' noncoding region of hepatitis C virus
20. Translation of human hepatitis C virus RNA in cultured cells is mediated by an internal ribosome-binding mechanism
21. Inhibition of hepatitus C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes
22. Poliovirus chimeras replicating under the translational control of genetic elements of hepatitis C virus reveal unusual properties of the internal ribosomal entry sire of hepatitis C virus
23. Acute toxicology and pharmacokinetic assessment of a ribozyme (ANGIOZYME) targeting vascular endothelial growth factor receptor mRNA in the cynomolgus monkey
24. Ribozyme pharmacokineric screening for predicting pharmacodynamic dosing regimes
25. Pharmacokinetics of an antiangiogenic ribozyme (ANGIOZYME) in the mouse